Direct-to-Patient. Patient Journey. End-to-end operating model.
Direct-to-patient channel design across intake, telehealth-enabled evaluation, reimbursement, fulfillment, support, longitudinal data capture, and long-term persistence.
End-to-End Patient Journey
Context
Patient entry, intake, onboarding, follow-through, and support across telemedicine, payer, and home-based models.
Evidence
Home diagnostics, telemedicine coordination, patient support workflows, and longitudinal engagement models.
Role
- Designed and operated patient-entry and follow-through workflows
- Built home-based support and telemedicine-linked models
- Handled patient interaction, scheduling, and continuity design
Payer, Access, and Telemedicine Operations
Context
Reimbursement, claims, scheduling, clinic coordination, and medical-necessity workflows in patient-facing programs.
Evidence
Blue Cross Blue Shield of Texas (BCBSTX), patient recruitment, co-pay strategy, claims processing, telemedicine coordination, clinic workflow, and medical-necessity support.
Role
- Designed reimbursement and access workflows for BCBSTX-linked programs
- Built claims, scheduling, SOP, and partner-operating processes
- Coordinated clinics, televisits, and medical-necessity support
DTP Operating Model and Platform Leadership
Context
Workflow logic, shared data environments, telemetry, reporting, routing, and platform operations.
Evidence
GlucoMON · GlucoDYNAMIX · GlucoMON-ADMS · Rarify · BEYONDXLH · Philips Virtual Care Management
Role
- Built device-to-decision systems spanning capture, transmission, and action
- Developed Rarify as a collaborative metabolic-condition platform
- Led BEYONDXLH as a longitudinal Phase IV program
Data, Persistence, and Program Governance
Context
Longitudinal signal, targeting, adherence, standards-of-care visibility, and program-level governance.
Evidence
Risk stratification, HEDIS visibility, early reinforcement logic, BEYONDXLH, Rarify eDiary, South Texas population work.
Role
- Used objective evidence to clarify patient targeting and support intensity
- Designed standards-of-care visibility and patient-education programs
- Built reinforcement-driven support models
Partner Ecosystem and Vendor Management
Context
CRO, eCOA, device, telehealth, platform, and commercialization vendors across clinical and patient-facing environments.
Evidence
IQVIA · Thread Research · CRO procurement · eCOA vendors · device logistics · AT&T · McKesson · NHS
Role
- Led procurement and vendor management across CROs, eCOA, and device vendors
- Participated in vendor performance management and CAPA resolution
- Structured partner workflows and operating processes
Commercial Drug Patient Journey Experience
Context
Commercial rare-disease therapies with post-launch patient programs and longitudinal data capture.
Evidence
Crysvita: $87.3M → $410.0M (2019–2024). Dojolvi: $6.4M → $88.0M (2020–2024). Combined: $145.3M → $498.0M (2020–2024).
Role
- BEYONDXLH Phase IV Lead (Yale School of Medicine, XLH Network)
- Innovation Lab Founder and Leader (~54-person team)
- Rarify Platform Lead; global pivotal Phase III support for Dojolvi
Category matrix
| Theme | Context | Evidence | Role |
|---|---|---|---|
| Companies and Health-System Context | Commercial pharma, payer, provider, digital health, and virtual care environments | Ultragenyx · Philips Virtual Care Management · Blue Cross Blue Shield of Texas (BCBSTXTX) · McKesson · AT&T · NHS | Built, led, or operated patient-facing systems, partner programs, and digital platforms across these environments |
| Commercial Drug Patient Journey Experience | Commercial rare-disease therapies with post-launch patient programs | Crysvita / Dojolvi growth metrics and related program work | Led BEYONDXLH; founded and led Innovation Lab; led Rarify; supported global pivotal Phase III Dojolvi work |
| Endocrinology, CGM, and Diabetes Technology | Continuous glucose data and endocrine-care workflows | Remote telemetry systems, Sugar Surfing, Diabetes Housecall, endocrinologist collaboration | Built glucose-telemetry systems; worked with endocrine care teams; co-authored Sugar Surfing |
| Payer, Access, and Telemedicine Operations | Reimbursement, claims, scheduling, clinic coordination, and medical-necessity workflows | BCBSTX programs, patient recruitment, co-pay strategy, claims processing, televisit coordination | Designed access workflows; built claims, SOP, and scheduling processes; coordinated telemedicine and medical-necessity support |
| DTP Operating Model and Platform Leadership | Workflow orchestration, shared data, telemetry, and platform operations | GlucoMON, GlucoDYNAMIX, GlucoMON-ADMS, Rarify, Philips Virtual Care Management | Built device-to-decision systems; developed collaborative platforms; led connected-care work |
| Data, Persistence, and Program Governance | Targeting, longitudinal signal, adherence, and standards-of-care visibility | Risk stratification, HEDIS visibility, reinforcement logic, BEYONDXLH, South Texas population work | Used evidence to redesign targeting; structured standards-of-care programs; built reinforcement-driven support models |